Safety, Tolerability, and Preliminary Efficacy Study of ALS-357 in Patients With Cutaneous Metastatic Melanoma
NCT ID: NCT00701987
Last Updated: 2010-02-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
12 participants
INTERVENTIONAL
2008-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Topical SOR007 Ointment for Cutaneous Metastases
NCT03101358
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic Malignant Melanoma
NCT00104897
Study to Investigate the Absorption, Distribution, Metabolism and Elimination of [14C]GSK1120212
NCT01387204
Study of AS1409 in Patients With Either Metastatic Renal Cell Carcinoma or Metastatic Malignant Melanoma
NCT00625768
Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function
NCT00118170
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
ALS-357 applied topically twice weekly for four weeks.
ALS-357
Topical application of ALS-357
2
ALS-357 applied topically every other day for four weeks.
ALS-357
Topical application of ALS-357
3
ALS-357 applied topically once daily for four weeks.
ALS-357
Topical application of ALS-357
4
ALS-357 applied topically twice daily for four weeks.
ALS-357
Topical application of ALS-357
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ALS-357
Topical application of ALS-357
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Study Participants must have 2 sites of cutaneous metastatic melanoma that can not be removed with surgery.
* Study Participants may have been previously treated with chemotherapy or immunotherapy but not with in 4 weeks of first dose of study treatment.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Advanced Life Sciences, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Advanced Life Sciences
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Timothy Kuzel, MD
Role: PRINCIPAL_INVESTIGATOR
Robert H. Lurie Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Robert H. Lurie Comprehensive Cancer Center, Northwestern University
Chicago, Illinois, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Timothy Kuzel, MD
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Timothy Kuzel, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ALS-357-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.